SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.
SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).
In the pivotal clinical trials, the most common solicited adverse reactions observed were pain, redness, and swelling at the injection site, myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.
*Data from the phase 3 ZOE-50 (≥50 years of age) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years of age from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.1,2 See study designs on the Efficacy page for details.
Counsel your patients on shingles prevention
Having an effective conversation with your patients is the key to vaccination.
These entertaining and informative videos will help guide you through the process.
Want to brush up on your SHINGRIX knowledge? We offer a range of educational videos on topics that include highlights of the pivotal trials, MOA, and reconstitution. Check out our On-Demand Videos.
CDC states that SHINGRIX is recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years.3
SHINGRIX is not indicated for prevention of herpes zoster-related complications.
CDC=Centers for Disease Control and Prevention.